N,N-Dimethyltryptamine

Piedmont Lithium Reports Q4 & Full Year 2023 Results

Retrieved on: 
Thursday, February 22, 2024
EV, Electric Vehicles, Automotive, General Automotive, Chemicals, Plastics, Automotive Manufacturing, Alternative Energy, Manufacturing, Energy, Mining, Minerals, Natural Resources, Lithium, N,N-Dimethyltryptamine, Concentrate, Sale, Workforce, Classification, Weather, District court, NAL, Insurance, Investment

$29.2 million accrued at December 31, 2023 for settlements in 2024 associated with spot shipments in 2023, negatively impacting Q4’23 revenue and gross profit.

Key Points: 
  • $29.2 million accrued at December 31, 2023 for settlements in 2024 associated with spot shipments in 2023, negatively impacting Q4’23 revenue and gross profit.
  • In Q1’24, we sold our holdings in Sayona Mining and a portion of our holdings in Atlantic Lithium for approximately $49.1 million.
  • In Q4’23, NAL produced 34.2 thousand dmt and shipped 23.9 thousand dmt, of which 14.2 thousand dmt were sold to Piedmont.
  • In November 2023, Sayona released initial drill results from the 2023 drill campaign at NAL, identifying multiple thick, high-grade, spodumene-bearing pegmatites.

Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

Retrieved on: 
Tuesday, March 7, 2023
Mental, Phase, CFB, BDI, Anxiety, Depression, Beck Depression Inventory, N,N-Dimethyltryptamine, IV, Safety, Major depressive disorder, Beck, Patient, MDD, MADRS, Pharmaceutical industry, N

LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces further positive results from the Company’s Phase IIa trial of SPL026, the first placebo-controlled study of a short-duration psychedelic for the treatment of Major Depressive Disorder (“MDD”). The trial investigated the efficacy and safety of a 21.5mg intravenous (“IV”) dose of SPL026, N,N-Dimethyltryptamine (“DMT”), with supportive therapy in 34 patients with moderate/severe MDD. Analyses of additional secondary and exploratory endpoints, including effects on self-reported depression, anxiety and wellbeing, demonstrated that patients receiving at least a single dose of IV SPL026 with supportive therapy experienced clinically relevant improvements in function and mood, further supporting previously announced topline efficacy results.

Key Points: 
  • The trial investigated the efficacy and safety of a 21.5mg intravenous (“IV”) dose of SPL026, N,N-Dimethyltryptamine (“DMT”), with supportive therapy in 34 patients with moderate/severe MDD.
  • The two-staged study included a two-week blinded, randomized, placebo-controlled phase followed by a 12-week open-label phase, in which all participants received a single dose of SPL026.
  • SPL026 with supportive therapy also demonstrated a rapid onset and durable antidepressant effect, as assessed by the Montgomery-Asberg Depression Rating Scale (“MADRS”).
  • Further analysis of the Phase IIa dataset is ongoing and full trial results will be submitted for publication in a peer-reviewed journal.

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Retrieved on: 
Thursday, March 2, 2023
National Institute of Neurological Disorders and Stroke, Doctor of Philosophy, University of Oxford, NFL, Oxford University Press, Biomedical sciences, Research, Journal of Neurotrauma, Journal, Science, Patient, Editorial board, Algernon, A Practical Guide to a Spectacular Suicide, MD, Norman, George Washington University School of Medicine & Health Sciences, Diagnosis, DMT, N,N-Dimethyltryptamine, AFL, Washington University in St. Louis, Washington University School of Medicine, Neurology, NINDS, Traumatic brain injury, DSM-IV codes, TBI, National Football League, CSE, AGN, Medical device, Stroke

Dr. Brody, MD, PhD is a board-certified neurologist with both a research and a clinical specialization in TBI and neurodegenerative diseases.

Key Points: 
  • Dr. Brody, MD, PhD is a board-certified neurologist with both a research and a clinical specialization in TBI and neurodegenerative diseases.
  • Dr. Brody was the Norman J. Stupp Professor of Neurology at the Washington University School of Medicine in St. Louis.
  • Dr. Brody was also the Washington University site director for the National Football League (NFL) Neurological player care program.
  • Dr. Brody is the editor in chief of the Journal of Neurotrauma and a member of the Editorial Board of Acta Neuropathologica.

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Retrieved on: 
Tuesday, February 21, 2023
Accident, Brain, Glasgow Coma Scale, Excitotoxicity, Tropomyosin receptor kinase B, Messenger, Human, Trial of the century, TBI, BDNF, AGN, Patient, DMT, Traumatic brain injury, Stroke, Vehicle registration plates of Nepal, N,N-Dimethyltryptamine, CSE, Reactive oxygen species, Nursing, Pharmaceutical industry

AGN Neuro has an active stroke research program underway and is currently conducting a Phase 1 DMT study in the Netherlands at the Centre for Human Drug Research.

Key Points: 
  • AGN Neuro has an active stroke research program underway and is currently conducting a Phase 1 DMT study in the Netherlands at the Centre for Human Drug Research.
  • AGN Neuro, in consultation with its TBI advisors, may plan and conduct certain preclinical research to help better guide the planned Phase 2 clinical study.
  • DMT is an agonist of sigma-1, a part of the body’s natural defense against physiological stresses, which is elevated following TBI.
  • AGN Neuro is also pleased to announce that it has appointed global TBI expert Dr. Andrew Maas as a scientific and medical advisor to help guide its TBI research program.

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Retrieved on: 
Wednesday, January 25, 2023
Safety, Patient, MDD, N,N-Dimethyltryptamine, Chief scientific officer, Phase, Depression, Grammatical mood, Data analysis, GMT, Major depressive disorder, EST, Pharmaceutical industry

The trial investigated the efficacy and safety of intravenous (“IV”) SPL026, with supportive therapy, in 34 patients with moderate/severe MDD.

Key Points: 
  • The trial investigated the efficacy and safety of intravenous (“IV”) SPL026, with supportive therapy, in 34 patients with moderate/severe MDD.
  • Participants who entered the trial on pharmacological antidepressant medication were withdrawn from their treatment prior to dosing.
  • Patients were dosed with a short IV infusion of 21.5mg of SPL026, resulting in a 20 to 30-minute psychedelic experience.
  • It was encouraging to see that SPL026 demonstrated a favourable safety and tolerability profile in MDD patients in this study, consistent with our Phase I study.

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Retrieved on: 
Wednesday, November 16, 2022
Stroke, N,N-Dimethyltryptamine, CHDR, Pharmacokinetics, Patient, LSD, Amazon, Brain-derived neurotrophic factor, Drug development, Niacin, Rehabilitation, Chronic kidney disease, AGN, Chronic cough, Psilocybin, Ketamine, CSE, Human, IPF, Animal, DMT, Trial of the century, Safety, Brain, Constraint-induced movement therapy, Pharmaceutical industry, Medical imaging

The company plans to open enrollment shortly and dose the first subject of the study in December 2022.

Key Points: 
  • The company plans to open enrollment shortly and dose the first subject of the study in December 2022.
  • We are very excited to be initiating our DMT clinical stroke research program with our Phase 1 study at CHDR in the Netherlands, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.

Beckley Psytech Successfully Completes Phase I Clinical Study of Lead Candidate BPL-003, a Novel Benzoate Formulation Of 5-MeO-DMT

Retrieved on: 
Tuesday, November 15, 2022
Research, Mental Health, Clinical Trials, Biotechnology, Alternative Medicine, Managed Care, Pharmaceutical, Health, Science, Other Science, 5-Methoxy-N,N-diisopropyltryptamine, MDD, TRD, Depression, N,N-Dimethyltryptamine, MHRA, Pharmacokinetics, Safety, Physician, CSO, Depression (mood), Psilocybin, Beckley Foundation, Patient, Treatment, Pharmaceutical industry

The double-blind, randomised, single ascending dose study ( NCT05347849 ) explored the safety, tolerability and pharmacokinetics of BPL-003 in combination with psychological support in 44 psychedelic-nave participants.

Key Points: 
  • The double-blind, randomised, single ascending dose study ( NCT05347849 ) explored the safety, tolerability and pharmacokinetics of BPL-003 in combination with psychological support in 44 psychedelic-nave participants.
  • Initial results show a dose-proportional pharmacokinetic (PK) profile and good tolerability with no serious adverse events reported.
  • With the robust data generated thus far from this Phase I study, Beckley Psytech is now preparing to initiate its MHRA-approved Phase IIa studies evaluating BPL-003 in Treatment Resistant Depression and Alcohol Use Disorder in Q4 2022.
  • Cosmo Feilding Mellen, CEO of Beckley Psytech, added: Beckley Psytech is making great progress in bringing this innovative formulation of 5-MeO-DMT to patients living with underserved conditions like Treatment Resistant Depression.

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

Retrieved on: 
Monday, October 24, 2022
MBBS, LSD, Chronic cough, N,N-Dimethyltryptamine, Chronic kidney disease, DMT, Stroke, IPF, Animal, CGMP, Drug development, Depression, Research, Lists of diseases, AGN, Independent agencies of the United States government, Company, Psychiatry, Schizophrenia, Substance-related disorder, CSE, IP, CTA, Yale School of Medicine, Psilocybin, Amazon, GLOBE, Government, Biomedical Research, Human, Pharmaceutical industry, Yale University, Medicine

As part of the CTA, Algernon will provide cGMP DMT for the study.

Key Points: 
  • As part of the CTA, Algernon will provide cGMP DMT for the study.
  • In return, Algernon will jointly own intellectual property around the clinical use of DMT arising from the study (IP) developed jointly by Algernon and Yale, and the option to negotiate licenses to both IP developed jointly and IP developed solely by Yale.
  • In addition, the Company will receive data from the study, which may assist in its DMT stroke research program.
  • After careful consideration, we chose to support Dr DSouzas clinical DMT study and work with Yale University, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Retrieved on: 
Friday, October 14, 2022
Molecule, LSD, Chronic cough, N,N-Dimethyltryptamine, Chronic kidney disease, DMT, Stroke, Science, IPF, Animal, Policy, Ethics, Family, DMT: The Spirit Molecule, Patient, Drug development, Brain, Music, Leiden University Medical Center, AGN, Neurogenesis, Trial of the century, Company, Ketamine, Industry, Constraint-induced movement therapy, CSE, Rehabilitation, Psilocybin, GLOBE, Clinical trial, Keynote, Pharmacy, Human, Pharmaceutical industry

Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.

Key Points: 
  • Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.
  • Algernon is very fortunate to have Dr. Rick Strassman as a key opinion leader on our DMT stroke research program, said Moreau.
  • Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.

Scientists Create Non-Psychedelic Compound with Same Anti-depressant Effect

Retrieved on: 
Wednesday, September 28, 2022
Mental Health, Research, Other Natural Resources, Other Health, Alternative Medicine, Health, Other Science, Science, Natural Resources, Tao, Selective serotonin reuptake inhibitor, National, Depression, Human, THP, LSD, DARPA, Patient, UNC, 5-HT2A, R-69, Anxiety, Research, Hallucination, Psychiatry, Eugene Higgins, Mouse, Serotonin, Doctor of Philosophy, DMT, Â, UCSF, Duke, Ketamine, Michael Hooker, FDA, MD, UNC School of Medicine, University of North Carolina at Chapel Hill, Stanford University, AstraZeneca, Permeability, Tony Hawk's Pro Skater 1 + 2, Department, Mount Sinai, Brain, Zehnder Confair, Psilocybin, Esketamine, Ellman, Neurochemistry, Defense, University of California, San Francisco, Protein, Cell, N,N-Dimethyltryptamine, Substance abuse, SSRI, Department of Defense Office of Inspector General, Multimedia, Neuron, Pharmaceutical industry, Yale University, Medicine, Pharmacology, Chemistry, Nature

Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.

Key Points: 
  • Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.
  • Other scientists speculate that if the trip could be eliminated from such drugs, then only the therapeutic effects might remain.
  • We were basically running a chemistry experiment to see if we could create a compound to activate 5-HT2A.
  • It would be a game changer to create a one-dose, long-acting therapy to help people with treatment-resistant depression and other conditions.